Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2014

01-04-2014 | Neuro-oncology (M Gilbert, Section Editor)

Update on Anti-angiogenic Treatment for Malignant Gliomas

Authors: John F. de Groot, Jacob J. Mandel

Published in: Current Oncology Reports | Issue 4/2014

Login to get access

Abstract

Malignant gliomas are the most common primary brain tumor found in adults. Unfortunately, the prognosis for these type of tumors remains dismal despite aggressive treatment with surgical resection, radiation and chemotherapy. Therefore, therapeutics aimed at disrupting the angiogenesis of these tumors is being utilized in to improve survival outcomes and quality of life. This paper reviews the history of antiangiogenic agents in malignant gliomas, discusses the FDA approval of bevacizumab as monotherapy in recurrent glioblastoma and the subsequent controversy, and analyzes the most recent newly diagnosed trials of RTOG 0825 and AVAglio. Additionally, the results of the latest trials with antiangiogenic agents and possible biomarkers are reviewed. Multiple questions remain regarding the potential benefit of antiangiogenic treatments in patients with glioblastoma. Future clinical trials should be designed to learn more about these drugs, to optimize their future use.
Literature
1.
2.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef
3.
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–18. doi:10.​1007/​s00401-010-0781-z.PubMedCrossRef
4.
5.
Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152–60.PubMedCrossRef
6.
Chi AS, Gregory Sorensen A, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14(6):621–36.PubMedCrossRef
7.
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4–6.PubMedCrossRef
8.
Wong MLH, Prawira A, Kaye AH, Hovens CM. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci. 2009;16(9):1119–30.PubMedCrossRef
9.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef
10.
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.PubMedCrossRef
11.
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.PubMedCrossRef
12.
Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. Natl Cancer Inst. 1972;48:347–56.
13.
Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003;62:297–303.PubMedCrossRef
14.
Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131–8.PubMedCrossRef
15.•
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40. doi:10.​1200/​JCO.​2008.​19.​8721. Multi-center phase II study of bevacizumab or bevacizumab plus irinotecan in recurrent glioblastoma showing improvement in radiographic response and 6 month PFS compared to historical controls leading to FDA Approval. PubMedCrossRef
16.•
Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5. N.I.H. phase II study of bevacizumab alone showing improvement in radiographic response and 6 month PFS recurrent glioblastoma compared to historical controls leading to FDA Approval. PubMedCentralPubMedCrossRef
17.
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572–8.PubMed
18.
Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.PubMedCentralPubMedCrossRef
19.
Macdonald DR, Cascino TL, Schold SCJ, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.PubMed
20.
Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.PubMedCentralPubMedCrossRef
21.
Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779–87.PubMedCrossRef
22.
Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009;6(3):513–26.PubMedCrossRef
23.•
Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab in patients with newly diagnosed glioblastoma. Proc Am Soc Clin Oncol. 2013; Abstract 1. Phase 3 double-blind placebo-controlled trial evaluating the addition of bevacizumab to the current standard of care (Stupp regimen) in patients with newly diagnosed glioblastoma that did not show a significant improvement in PFS or OS.
24.•
Wick W, Cloughesy TF, Nishikawa R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression in the phase III AVAglio trial of bevacizumab plus temozolomide plus radiotherapy in newly diagnosed glioblastoma patients. Proc Am Soc Clin Oncol. 2013; Abstract 2002. Phase 3 double-blind placebo-controlled trial evaluating the addition of bevacizumab to the current standard of care (Stupp regimen) in patients with newly diagnosed glioblastoma that showed a significant improvement in PFS of 3 months but no benefit in OS.
25.
Wefel JS, Pugh SL, Armstrong TS, et al. Neurocognitive function outcomes in patients with glioblastoma enrolled in RTOG 0825. Proc Am Soc Clin Oncol. 2013; Abstract 2004.
26.
Armstrong TS, Won M, Wefel JS, Gilbert MR et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Proc Am Soc Clin Oncol. 2013; Abstract 2003.
27.
Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Oncol Targets Ther. 2013;6:371–89. doi:10.​2147/​OTT.​S38628. Published online 2013 April 15.CrossRef
28.
29.
Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neuro-Oncol. 2008;88(3):339–47.CrossRef
30.
Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-Oncology. 2009;11(5):550–5.PubMedCentralPubMedCrossRef
31.
de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology. 2010;12(3):233–42.PubMedCentralPubMedCrossRef
32.
33.
Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol. 2011;69(3):586–92. doi:10.​1002/​ana.​22336.PubMedCrossRef
34.
35.
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT. J Clin Oncol. 2008;26(25):4189–99. doi:10.​1200/​JCO.​2007.​11.​5964.PubMedCrossRef
36.
Herrlinger U, Schaefer N, Steinbach JP, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed MGMT non-methylated glioblastoma patients: first results from the randomized multicenter GLARIUS trial. Proc Am Soc Clin Oncol. 2013; Abstract LBA2000.
37.•
Taal W, Oosterkamp HM, Walenkamp AM, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. Proc Am Soc Clin Oncol. 2013; Abstract 2001. Phase II study showing benefit in 6 month PFS and OS with combination of treatment with bevacizumab and lomustine compared to either agent alone. First bevacizumab study in recurrent glioblastoma to show benefit in overall survival as a primary endpoint.
38.
39.
Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16):2712–8. doi:10.​1200/​JCO.​2009.​26.​6650.PubMedCrossRef
40.
Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated 06-methylguanine-DNA-methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized open-label, controlled, phase III CENTRIC study. Proc Am Soc Clin Oncol. 2013; Abstract LBA2009.
41.
Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical cancer research: an official journal of the American Association for Cancer Research. Clinical Trial, Phase II, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t. 2008;14(21):7068–73.
42.
Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;1513(4):1253–9.CrossRef
43.
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17(9):2762–71.PubMed
44.
Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007;13:223–30.PubMedCentralPubMedCrossRef
45.
Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271–8.PubMedCentralPubMedCrossRef
46.
Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 2010;12(12):1300–10.PubMedCentralPubMed
47.
Sulman EP, Won M, Blumenthal DT, et al. Molecular predictors of outcome and response to bevacizumab based on analysis of RTOG 0825, a phase III trial comparing chemoradiation with and without bevacizumab in patients with newly diagnosed glioblastoma. Proc Am Soc Clin Oncol. 2013; Abstract LBA2010.
48.
Vredenburgh J, Desjardins A, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9.PubMedCrossRef
49.
Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714–21.PubMedCrossRef
50.
51.
Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neurol Oncol. 2010;12(5):508–16. doi:10.​1093/​neuonc/​nop063.
Metadata
Title
Update on Anti-angiogenic Treatment for Malignant Gliomas
Authors
John F. de Groot
Jacob J. Mandel
Publication date
01-04-2014
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2014
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0380-6

Other articles of this Issue 4/2014

Current Oncology Reports 4/2014 Go to the issue

Palliative Medicine (A Jatoi, Section Editor)

Fighting Insomnia and Battling Lethargy: The Yin and Yang of Palliative Care

Invited Commentary

Dangers of “Confirmatory” Cancer Trials That Fail To Actually Test the Original Hypothesis

Palliative Medicine (A Jatoi, Section Editor)

When and When Not To Use Testosterone for Palliation in Cancer Care

Neuro-oncology (M Gilbert, Section Editor)

Targeted Therapy in Gliomas

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits